Recombinant Pseudomonas Vaccine: Technological Aspects of Obtaining and Evaluating Quality Indicators
Abstract
For an aim to prevent Pseudomonas aeruginosa, a candidate recombinant vaccine has been developed. This vaccine – (RPV) was based on two protective proteins of P. aeruginosa: the outer membrane protein F (OprF) and the recombinant truncated form of the Exotoxin A (toxoid) that were adsorbed on the aluminum hydroxide. The optimal immunization schedule for mice included two intraperitoneal administrations with a two-week interval. RPV promoted to increase survival rates in challenged immunized mice and stimulated humoral and innate immune responses. During preclinical studies, we confirmed the immunogenicity of the vaccine that had not pyrogenicity, acute and chronic toxicity, allergenicity and immunotoxicity.
Keywords: Pseudomonas aeruginosa, outer membrane protein F (OprF), toxoid, Pseudomonas Recombinant Vaccine (PRV)
References
[1] Grimwood, K., et al. (2015) Vaccination against respiratory Pseudomonas aeruginosa infections. Hum. Vaccin. Immunothe, vol. 11, issue 1, pp. 14-20. https://doi.org/10.4161/hv.34296.
[2] Lazareva, A.V., et al. (2015) Pseudomonas aeruginosa: Pathogenicity, Pathogenesis and Diseases. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya, vol. 17, issue 3, pp. 170-186.
[3] World Health Organization. (2017) WHO publishes list of bacteria for which new antibiotics are urgently needed. Geneva: World Health Organization.
[4] Merakou, C., et al. (2018) Progress Toward the Elusive Pseudomonas aeruginosa Vaccine. Surg Infect (Larchmt), vol. 19, issue 8, pp. 757-768. https://doi.org/10.1089/sur.2018.233
[5] Kaloshin A.A., et al. (2011) Obtaining recombinant forms of the outer membrane protein F of Pseudomonas aeruginosa and assessment of their immunogenic properties. Applied Biochemistry and Microbiology, vol. 47, issue 8, pp. 780-788. https://doi.org/10.1134/S0003683811080060
[6] Kaloshin A.A., et al. (2013) Preparation of Recombinant Atoxic Form of Exotoxin A from Pseudomonas aeruginosa. Bulletin of Experimental Biology and Medicine, vol. 154, issue 3, pp. 346-350. https://doi.org/10.1007/s10517-013-1947-1
[7] Gilleland H.E. Jr, et al. (1984) Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice. Infect Immun, vol. 44, issue 1, pp. 49-54.
[8] Michalska, M. and Wolf, P. (2015) Pseudomonas Exotoxin A: optimized by evolution for effective killing. Front Microbiol, vol. 6, pp. 963. https://doi.org/10.3389/fmicb.2015.00963
[9] Kaloshin A.A., et al. (2016) Assessment of Protective Properties of the Recombinant Complex of the Outer Membrane Protein F and the Toxoid of Pseudomonas aeruginosa. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, vol. 71, issue 1, pp. 1-5. https://doi.org/10.15690/vramn584
[10] Delves P.J., et al. (2017) Roitt's essential immunology, 13th edition. Publisher: Chichester, West Sussex: John Wiley & Sons, Ltd.
[11] Caucheteux SM., et al. (2016) IL-1β enhances inflammatory TH2 differentiation. J Allergy Clin Immunol, vol. 138, issue 3, pp. 898-901. https://doi.org/10.1016/j.jaci.2016.02.033
[12] Liu J., et al. (2011) Early production of IL-17 protects against acute pulmonary Pseudomonas aeruginosa infection in mice. FEMS Immunol Med Microbiol, vol. 61, issue 2, pp. 179-88. https://doi.org/10.1111/j.1574-695X.2010.00764.x
[13] Bayes H.K., et al. (2014) T helper cell subsets specific for Pseudomonas aeruginosa in healthy individuals and patients with cystic fibrosis. PLoS One, vol. 9, issue 2, pp. e90263. https://doi.org/10.1371/journal.pone.0090263
[14] Di Paolo N.C. and Shayakhmetov D.M. (2016) Interleukin 1α and the inflammatory process. Nat Immunol, vol. 17, issue 8, pp. 906-913. https://doi.org/10.1038/ni.3503.
[15] Santarlasci V., et al. IL-1 and T Helper Immune Responses. Front Immunol, vol. 4, pp. 182. https://doi.org/10.3389/fimmu.2013.00182